Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300276 | 1.00 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL1862470 | 1.00 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL25780932 | 0.90 | BTK (0.50) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL10343938 | 0.87 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL3702152 | 0.87 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL3702157 | 0.87 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL1406894 | 0.87 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA | |
| Methyl Alcohol SCHEMBL28082230 | 0.85 | BTK (0.59) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL4380397 | 0.84 | KMT2A (0.44) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL4380399 | 0.84 | KMT2A (0.44) | BTKKDM1AMAOBCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091438-A1 | CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2021-12-02 | — | — | US | disclosed |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | BTK 88/4885KDM1A 3294/4885MAOB 1629/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | BTK 1677/4885KDM1A 984/4885MAOB 2003/4885 |
| US-20020082420-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | PKD1, REN, CYP11B1 | BTK 1769/4885KDM1A 3903/4885MAOB 1019/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | BTK 4740/4885KDM1A 2331/4885MAOB 4693/4885 |
| US-20210369710-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | BTK 2234/4885KDM1A 2986/4885MAOB 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.